所有制结构改革视角下的国有医药企业创新行为分析

On Innovative Behavior of State-owned Pharmaceutical Enterprises from the Perspective of Ownership Structure Reform

目的:根据国有医药企业所具有的经济效益、社会责任和政治任务的特殊性,分析其在实施国家创新发展战略中的引领和示范作用,提出提升国有医药企业创新能力的路径。方法:基于医药所有制改革和创新政策的阐述,采用DEA(Data Envelopment Analysis,数据包络分析)的Malmquist(生产效率变化测算)指数,动态分析国有医药企业的创新绩效。采用Panel data(面板数据)模型对国有医药企业创新绩效进行实证分析。结果与结论:国有医药企业在生物产品制造业子领域取得了较好的创新绩效;国有企业是基于创新活动实现我国医药经济增长的主要力量,但还存在着研发资源过于集中和过剩现象。提升国有医药企业创新能力的路径,包括发挥其整合辐射作用、微观合作、组织结构调整和跨区域整合等。

Objective： To analyze the leading and exemplary role of the state-owned pharmaceutical enterprises in the implementation of national innovation and development strategies on the basis of their particularity in the economy, social responsibility and political task, and to put forward the methods of enhancing the innovative capacity of the state-owned pharmaceutical enterprises. Methods： Based on the analysis of medical ownership reform and innovation policy, the Malmquist index of Data Envelopment Analysis （DEA） was used to dynamically analyze the innovation performance of state-owned pharmaceutical enterprises. The panel data model was used to do the empirical analysis of the innovation performance of state-owned pharmaceutical enterprises. Results and Conclusion： The state-owned enterprises have fulfilled good achievement in innovation in the subfield of biological products manufacturing industry. The State - owned enterprises are the main force to achieve pharmaceutical economic growth of China, but the phenomenon of excessive concentration and surplus of research and development resources still exist. The way to enhance innovation ability of the state-owned pharmaceutical enterprises consists of the market radiating and integrating, micro-cooperation, organizational restructuring and cross-regional integration, and so on.